YOLFTbeta
Xilio Development Inc

Xilio Development Inc

XLO · NASDAQ · Healthcare / Biotechnology

8.08USD-0.17 (-2.00%)

Price History

Full chart

Market Stats

Previous Close8.24
Open7.96
Day Range7.60 – 8.08
52-Week Range6.47 – 12.59
Volume7.58K
Market Cap58.81M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.32
Dividend Yield0.00%
Beta-0.12
50-Day Avg9.03
200-Day Avg8.59

About

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Rene Russo BCPS, Pharm.D.
  • Employees76
  • Headquarters828 Winter Street, Waltham, MA, United States, 02451, USA
  • Websitehttps://xiliotx.com

Leadership

  • Dr. Rene Russo BCPS, Pharm.D.President, CEO & Director · b. 1975
  • Mr. Christopher FrankenfieldCFO & COO · b. 1982
  • Mr. Kevin M. BrennanSenior Vice President of Finance & Accounting · b. 1970
  • Dr. Uli Bialucha Ph.D.Chief Scientific Officer
  • Mr. Nathan McBrideChief Information Officer
  • Mr. Benjamin S. Harshbarger J.D.Chief Legal Officer · b. 1969
  • Dr. Scott Coleman Ph.D.Chief Development Officer
  • Ms. Ruth du MoulinSenior Vice President of Medical Affairs

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue000006.34M43.77M
Growth (%)------+589.88%
Cost of Revenue240.00K1.06M1.50M1.85M1.90M1.64M1.54M
Gross Profit-240.00K-1.06M-1.50M-1.85M-1.90M6.34M42.23M
Gross Margin-----100.00%96.48%
Operating Expense18.79M53.50M73.55M87.30M77.23M66.93M84.21M
Operating Income-19.03M-54.56M-75.04M-89.15M-79.13M-60.58M-41.98M
Operating Margin------954.95%-95.92%
EBITDA-17.07M-53.55M-73.55M-87.30M-74.50M-58.00M-33.49M
EBITDA Margin------914.27%-76.53%
Net Income-17.31M-55.22M-74.30M-87.30M-76.40M-58.24M-35.04M
Net Income Margin------918.05%-80.05%
R&D14.26M43.91M51.19M59.20M52.14M41.21M56.04M
R&D as % of Total Revenue-----649.61%128.04%
Interest Expense0600.00K756.00K927.00K127.80K100.00K-
Interest Expense % of Total Revenue-----1.58%-

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets62.72M36.32M221.60M139.16M60.93M71.08M154.69M
Total Liabilities24.21M41.60M36.17M33.52M24.10M53.48M119.41M
Total Equity38.51M-5.29M185.43M105.65M36.83M17.60M35.27M
Cash48.84M19.24M198.05M120.39M44.70M55.29M137.53M
Total Debt18.63M21.89M20.74M19.94M12.50M8.14M6.95M
Net Debt-30.21M2.65M-177.32M-100.45M-32.20M-47.15M-130.58M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-17.84M-36.09M-80.75M-75.72M-68.62M-18.38M-4.99M
Investing Cash Flow-715.00K-2.19M-1.10M-1.87M-486.00K-36.00K-518.00K
Financing Cash Flow60.02M10.03M260.67M-69.00K-6.55M29.20M87.78M
Capital Expenditure715.00K2.19M1.10M1.87M486.00K36.00K518.00K
Free Cash Flow-18.56M-38.28M-81.85M-77.59M-69.11M-18.41M-5.51M
FCF to OCF104.01%106.06%101.36%102.47%100.71%100.20%110.38%

Earnings

Report DateMar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021May 24, 2021Sep 1, 2021Dec 2, 2021Mar 1, 2022May 12, 2022Aug 9, 2022Nov 9, 2022Mar 2, 2023May 9, 2023Aug 14, 2023Nov 9, 2023Feb 7, 2024Apr 1, 2024Aug 8, 2024Nov 7, 2024Mar 11, 2025May 8, 2025Aug 14, 2025Nov 13, 2025Mar 4, 2026May 12, 2026Aug 12, 2026Nov 12, 2026
EPS Estimate0.000.000.000.000.000.00-1.92-24.41-1.17-14.56-11.11-12.41-0.78-12.65-12.37-11.62-0.64-8.49-4.71-4.20-0.261.33-1.12-0.42-0.10-0.66-0.59-
EPS Actual-19.83-27.98-27.93-27.93-23.53-0.63-2.28-12.36-0.98-10.92-12.60-10.08-0.82-11.62-9.80-8.54-0.64-8.96-3.37-3.10-0.20-2.52-2.24-1.540.81-0.58-0.33-
Surprise-------18.75%49.37%16.24%25.00%-13.41%18.78%-5.13%8.14%20.78%26.51%0.00%-5.54%28.45%26.19%22.09%-289.47%-100.00%-266.67%907.70%11.68%44.07%-
Timing-------After-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-market-Pre-marketPre-marketPre-market--Pre-market-

Key Statistics & Ratios

Market Cap58.81M
Enterprise Value-70.91M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.92
Price / Book0.81
EPS-0.32
Book Value7.79
Revenue (TTM)64.09M
Gross Profit (TTM)53.30M
EBITDA-30.03M
Profit Margin-34.06%
Operating Margin-18.68%
Return on Equity-55.03%
Return on Assets-13.61%
Shares Outstanding6.58M
Shares Float3.40M
Beta-0.12
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 1 analystsTarget 20.00
  • Strong Buy
    1

Ownership Breakdown

Institutions
50.14%
Insiders
25.98%
Retail / Other
23.88%

Top Institutional Holders

  • Bain Capital Life Sciences Investors, LLC
    664.02K10.09%
  • Frazier Life Sciences Management, L.P.
    422.50K6.42%
  • Sio Capital Management, LLC
    152.46K2.32%
  • Vanguard Capital Management, LLC
    123.66K1.88%
  • Adage Capital Partners Gp LLC
    111.54K1.70%
  • Merck & Co Inc
    105.98K1.61%
  • Stonepine Capital Management Llc
    64.16K0.98%
  • Morgan Stanley - Brokerage Accounts
    57.49K0.87%
  • Renaissance Technologies Corp
    49.57K0.75%
  • AJU IB Investment Co Ltd
    47.70K0.72%
  • Geode Capital Management, LLC
    37.20K0.57%
  • FMR Inc
    36.56K0.56%
  • Vanguard Fiduciary Trust Co
    28.48K0.43%
  • Citadel Advisors Llc
    25.95K0.39%
  • Two Sigma Investments LLC
    14.54K0.22%
  • Velan Capital Investment Management LP
    14.29K0.22%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    142.44K2.16%
  • Fidelity Extended Market Index
    19.46K0.30%
  • Bridgeway Ultra-Small Company
    17.54K0.27%
  • Abante Quant Value FI
    15.63K0.24%

Stock Splits

  • Mar 16, 20261:14